Prosecution Insights
Last updated: November 04, 2026
Application No. 18/043,205

METHOD FOR BREEDING RECESSIVE GENETIC MALE STERILE LINE OF SPOROPHYTE

Final Rejection §103§112
Filed
Feb 27, 2023
Priority
Aug 27, 2020 — CN 202010879352.4 +1 more
Examiner
KUMAR, VINOD
Art Unit
1663
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Yunnan University
OA Round
2 (Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1196 granted / 1445 resolved
+22.8% vs TC avg
Strong +20% interview lift
Without
With
+20.3%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
34 currently pending
Career history
1477
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
21.9%
-18.1% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
48.6%
+8.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1445 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of objections and rejections 1. Claims 1, 2, 4-7, 9, 11 and 13 are pending. Claims 3, 8, 10, 12 and 14-20 are cancelled. Accordingly, claims 1, 2, 4-7, 9, 11 and 13 are examined on merits in the instant Office action. 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. 3. Rejection of Claims 1, 2, 4-7, 9, 11 and 13 under 35 U.S.C. 112(a), first paragraph, as failing to comply with the written description requirement is withdrawn in light of amendments to the claims filed in the papers of July 16, 2026 and upon further consideration. 4. Rejection of claim(s) 1, 2, 4-7, 9, 11 and 13 under 35 U.S.C. 103 as being unpatentable over Li et al. (CN 106834305 A, pages 1-24, English translation attached with the foreign document, Published March 16, 2017), and Ren et al. (The Plant Journal, 98:315-328, Published December 27, 2018 supplementary documents attached), and further in view of Zhang et al. (CN 102586278 A, pages 1-24, English translation attached with the foreign document, Published March 16, 2017), Wahler et al. (GenBank Sequence Accession NO. KF036176.1, pages 1-2, Published July 2013), Xu et al. (Rice, 7:5, pages 1-4, published 2014, supplementary documents attached) and Zhao et al. (J. Plant Biol., 59:496-505, Published 2016, supplementary documents attached) is withdrawn in light of amendments to the claims filed in the papers of July 16, 2026 and upon further consideration. Claim Rejections - 35 USC § 112 (Scope of Enablement) 5. Claims 1, 2, 4-7, 9, 11 and 13 remain rejected under the first paragraph of 35 U.S.C. § 112(a). While the specification is enabling for a method of breeding a recessive genetic male sterile line of a rice sporophyte, comprising transforming a rice male sterile mutant plant, Zhongjiu B-osabcg15 (carrying a mutation in the endogenous OsABCG15 gene), with a plant transformation vector designated pAR-Xi-Y-Bi-C, which comprises a multigene construct having the nucleotide sequences set forth in SEQ ID NOs: 6, 11, 17, 18 and 20, wherein expression of said multigene construct, followed by breeding, purity identification, and improvement of the genetic male sterile Zhongjiu B-osabcg15 sporophyte, results in production of a recessive genetic male sterile line of a rice sporophyte, it does not reasonably provide enablement for: (i) any sporophyte; (ii) any interference sequence directed to the gametophyte male sterility–related OsPTD1 gene; and (iii) producing a recessive genetic male sterile rice sporophyte line using any method that does not involve transformation with a plant transformation vector designated pAR-Xi-Y-Bi-C comprising said multigene construct. The specification does not enable a person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims, for the reasons of record stated in the Office action mailed April 16, 2026. Applicant primarily argues that the claims have been amended to overcome this rejection. Applicant’s arguments have been carefully considered but are deemed persuasive only in part. While most of the issues have been addressed through Applicant’s claim amendments, three issues identified in the body of the rejection remain pending, for the reasons of record. To overcome this rejection, Applicant is advised to do the following: (i) clearly recite in the claims that the plant is a rice sporophyte, so that the claims do not read on any sporophyte while relying on rice endogenous gene(s) to practice the method; (ii) clearly recite that the method involves plant transformation using the multigene construct; and (iii) move the limitation of claim 4 (i.e., SEQ ID NO: 20) into parent claim 1. In the absence of guidance or suggested claim amendments, it is maintained that undue experimentation would be required to increase or down-regulate expression of endogenous genes by means not involving plant transformation with an appropriate DNA construct directed to increasing expression of said genetic elements, in any plant species, including rice, as encompassed by the breadth of the claims. Accordingly, given the breadth of the claims, the unpredictability of the art, and the lack of guidance in the specification, as discussed above, it is maintained that undue experimentation would be required for one skilled in the art to make and use the claimed invention commensurate in scope with the claims. Conclusion 6. Claims 1, 2, 4-7, 9, 11 and 13 remain rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vinod Kumar whose telephone number is (571) 272-4445. The examiner can normally be reached on 8.30 a.m. to 5.00 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad A. Abraham can be reached on (571) 270-7058 The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA). /VINOD KUMAR/Primary Examiner, Art Unit 1663
Read full office action

Prosecution Timeline

Feb 27, 2023
Application Filed
May 18, 2025
Response after Non-Final Action
Apr 16, 2026
Non-Final Rejection mailed — §103, §112
Jul 16, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12757846
CANNABIS PLANT NAMED 'LPA004'
4y 8m to grant Granted Oct 13, 2026
Patent 12757861
TOMATO VARIETY NUN 00327 TOP
2y 2m to grant Granted Oct 13, 2026
Patent 12753413
RNA GUIDE GENOME EDITING IN CITRUS USING CRISPR-RIBONUCLEOPROTEIN COMPLEXES
4y 8m to grant Granted Oct 06, 2026
Patent 12751394
SOYBEAN VARIETY
3y 8m to grant Granted Oct 06, 2026
Patent 12751395
SOYBEAN VARIETY CE2020763
3y 8m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
99%
With Interview (+20.3%)
2y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1445 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month